The DiaChemo Principle:

We propose to develop a point-of-care device for quantification of chemotherapeutic drugs in small body fluid samples by highly selective nanoparticle extraction and liquid crystal detection incorporated in a microfluidic lab-on-a chip device (optofluidics based)allowing the real-time drug monitoring. This will improve the therapeutic outcome and reduced health care costs.

Expected impact and future development

  • Easy adaption of selective nanoparticles by ligand exchange to other drug molecules
  • Liquid crystal matrix follows nanoparticle or/and drug-metabolite hydrophobicity
  • Availability of easy and fast TDM will create the need for better drug monitoring

Read more on the website of DiaChemo.

Within the DiaChemo project LioniX International will develop a microfluidic platform (based on the TriPleX™ technology) exploiting multiple colors that can be used to detect wavelength specific absorption. Waveguide technology of LXI allows on-chip combination of multiple wavelengths in the visible light domain in order to measure with multiple wavelengths simultaneously, therefore creating a spectral fingerprint of the analyte of interest. In order to enhance the detection limit, the interaction between light and analyte can be increased by integrating folded waveguides structures within the microfluidic sensing window. Next to this, we will develop a ready-to-use TEC controlled micromixer module operating within required temperature range.